First production of a human protein with complex glycosylation in genetically modi...( p. About GlycoFi GlycoFi I...)

First production of a human protein with complex glycosylation in genetically modified yeast

p."

About GlycoFi

GlycoFi, Inc., privately held, was founded in 2000 with the mission of dramatically improving the capacity and cost of producing human therapeutic proteins, while simultaneously enhancing their efficacy and safety as therapeutics. The company harnesses the inherent advantages of yeast and other fungal-based protein expression systems by engineering these systems to produce correctly glycosylated human therapeutic proteins, thus greatly increasing the efficiency, fidelity and scalability at which those proteins can be made. For more information on GlycoFi, please visit the company's website at www.glycofi.com.

'"/>

28-Aug-2003

Page: 1 2 3
Related biology news :

1. First glimpse of DNA binding to viral enzyme
2. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
3. 2nd media alert First Scientific Conference on Childhood Leukaemia
4. First International Scientific Conference on Childhood Leukaemia
5. First ever standards linking climate change, biodiversity and poverty seek global peer review
6. First genetic comparison of purebred domestic dogs produces surprises
7. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
8. First target for childhood malaria vaccine
9. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
10. First flavors form a lasting impression
11. STN International launches Derwent World Patents Index First View

Post Your Comments:

(Date:5/16/2017)... 16, 2017 Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...

(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...

(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...

Breaking Biology News(10 mins):

[1] Bridge Patient Portal and MD EMR Systems Partner to Build Integration Between Bridge Patient Portal and GE Centricity EMR and CPS [3] NXT-ID Inc. Files 2016 Annual Report on Form 10-K [0] So You Think You Can Secure Your Mobile Phone with a Fingerprint?

(Date:10/12/2017)... ... October 12, 2017 , ... ... Rosalind™, the first-ever genomics analysis platform specifically designed for life science researchers ... honor of pioneering researcher Rosalind Franklin, who made a major contribution to ...

(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...

(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology ... drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription ... is able to cross the cell membrane and bind intracellular STAT3 and inhibit ...

(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...

Breaking Biology Technology:

[0] Rosalind™ Launches the Next Era of Genomics [0] Proscia Hosts Webinar on Digital Pathology Adoption Best Practices [0] Singh Biotechnology Receives Second FDA Orphan Drug Designation for its Novel Single Domain Antibody for the Treatment of Osteosarcoma by Targeting Intracellular STAT3 [0] Parks Associates: More Than 26 Million U.S. Broadband Households Will Have Professionally Monitored Security by 2021

Cached News:

Scientists identify genes that regulate allergic response to diesel fumes PDF invites scientists pursuing Parkinson's research to apply for funding Researchers show evolutionary theory adds up California pistachio industry threatened by potentially devastating disease

Chemical switch triggers critical cell activities Paleontologists to discuss 'gap' fossils that link fish and land animals Applied scientists create wrinkled 'skin' on polymers Lead with a poisonous electron shield